Answers are grounded in this paper and cite their sources.
This investigation sought to determine whether picropodophyllotoxin (PPT)—a primary bioactive compound extracted from the roots of Podophyllum hexandrum —exerts protective effects against inflammation triggered by lipopolysaccharide (LPS). Using cultured human pulmonary artery endothelial cells (HPAECs) stimulated with LPS, we assessed the modulatory effects of PPT on heme oxygenase-1 (HO-1), cyclooxygenase (COX-2), and inducible nitric oxide synthase (iNOS). Furthermore, the impact of PPT on iNOS, tumor necrosis factor-alpha (TNF-α), and interleukin-1β (IL-1β) was evaluated in LPS-challenged mice. The experimental results demonstrated that PPT upregulated HO-1 expression, blocked NF-κB activation, reduced COX-2/prostaglandin E2 and iNOS/nitric oxide (NO) production, and attenuated STAT protein phosphorylation. Additionally, PPT facilitated the nuclear translocation of Nrf2, enabling its binding to antioxidant response elements, which subsequently led to decreased IL-1β levels in LPS-exposed HPAECs. Notably, the PPT-mediated suppression of iNOS/NO was abolished when HO-1 was silenced via RNA interference. In the in vivo model, PPT markedly inhibited iNOS expression in pulmonary tissues and lowered TNF-α concentrations in bronchoalveolar lavage fluid. Overall, these findings demonstrate that PPT exerts anti-inflammatory and endothelial-protective effects in the pulmonary context and highlight its potential as a therapeutic candidate for acute lung injury and other pulmonary inflammatory disorders associated with endothelial dysfunction.
No takes yet. Share an insight, caveat, or question.
Cho et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: